Author： Campbell Jonathan D. Ramsey Scott D.
Publisher： Adis International
ISSN： 1170-7690
Source： PharmacoEconomics, Vol.27, Iss.3, 2009-01, pp. : 199-209
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Fulvestrant: benefits at acceptable costs in advanced breast cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 571, 2009-01 ,pp. :
Access to resources
Recommend
Costs of taxanes, capecitabine, quantified for breast cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 595, 2010-01 ,pp. :
Screening for breast cancer may cut future costs
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 339, 2001-01 ,pp. :
Management and Costs of Treating Lung Cancer Patients in a University Hospital
By Dedes K.J.
PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. :
US patient time costs for cancer "substantial"
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 523, 2007-01 ,pp. :